Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Applied Therapeutics Inc APLT

Healthcare Biotechnology
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare... see more

Recent & Breaking News (NDAQ:APLT)

SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders

Business Wire January 10, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation

Business Wire January 6, 2022

Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations

Newsfile January 4, 2022

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

GlobeNewswire January 3, 2022

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

GlobeNewswire December 16, 2021

Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

GlobeNewswire November 18, 2021

Applied Therapeutics Reports Third Quarter 2021 Financial Results

GlobeNewswire November 12, 2021

Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

GlobeNewswire October 25, 2021

Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

GlobeNewswire October 18, 2021

Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids

GlobeNewswire September 9, 2021

Applied Therapeutics Reports Second Quarter 2021 Financial Results

GlobeNewswire August 12, 2021

Applied Therapeutics Added to Russell Microcap® Index

GlobeNewswire June 28, 2021

Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association

GlobeNewswire June 25, 2021

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association

GlobeNewswire June 21, 2021

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

GlobeNewswire June 17, 2021

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewswire June 1, 2021

Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference

GlobeNewswire May 19, 2021

Applied Therapeutics Reports First Quarter 2021 Financial Results

GlobeNewswire May 11, 2021

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

GlobeNewswire April 7, 2021

Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

GlobeNewswire March 18, 2021